Sabine Emmers

Technical Development and Operations at Santhera Pharmaceuticals

Sabine Emmers's Professional Contact Details

Email (Verified)

****@santhera.com

Get Email Address

(646) 586-2113

Location

Basel, Basel-Stadt, Switzerland

Company

Santhera Pharmaceuticals

Person Seniority

entry

Person Functions

operations

Sabine Emmers's Current Company Details

Santhera Pharmaceuticals

• 83 Employees

pharmaceuticals

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product RaxoneÂ® is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for RaxoneÂ®, Santhera has filed a Marketing Authorization Application (MAA) in the European Union. Santhera develops RaxoneÂ® in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.

Public Symbol

SANN

Founded Year

2004

Organization Website

santhera.com

Organization Languages

English

Organization Revenue

4300

Current Technologies

google analytics